Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a beta3-adrenergic receptor agonist, used in overactive bladder (OAB) syndrome, to treat symptoms of urgency and increased frequency of urination, as well as incontinence.
It is administered orally once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (EMA 2017) makes it difficult to predict transfer into breastmilk, since while the low molecular weight, the pKa and the very long half-life would facilitate transfer, the very high volume of distribution would hinder it.
On the other hand, its low bioavailability implies minimal transfer into infant plasma, except in the neonatal period and in cases of prematurity when intestinal absorption may be increased.
Until there is more published data on this drug in relation to breastfeeding, known safer alternatives during the neonatal period and in the event of prematurity may be preferable.